2024
Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings?
Palacios C, Chowdhary V, Hao R, Danve A, Malinis M. Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings? PLOS ONE 2024, 19: e0306337. PMID: 38959249, PMCID: PMC11221665, DOI: 10.1371/journal.pone.0306337.Peer-Reviewed Original ResearchConceptsInterferon-gamma release assayDisease-modifying antirheumatic drugsInterferon-gamma release assay testLatent tuberculosis infectionNon-endemic settingsRheumatologic diseasesRisk factorsPositive interferon-gamma release assayLatent tuberculosis infection screeningLatent tuberculosis infection diagnosisPositive IGRA testMonths of rifampinLow-risk patientsRetrospective chart reviewTNF-alpha inhibitorsTB risk factorsTargeted LTBI screeningOutpatient rheumatology clinicDisease-modifying drugsIGRA testPatient demographicsAdult patientsChart reviewAntirheumatic drugsNon-endemic areas
2016
Incidence of systemic lupus erythematosus in a population-based cohort using revised 1997 American College of Rheumatology and the 2012 Systemic Lupus International Collaborating Clinics classification criteria
Ungprasert P, Sagar V, Crowson C, Amin S, Makol A, Ernste F, Osborn T, Moder K, Niewold T, Maradit-Kremers H, Ramsey-Goldman R, Chowdhary V. Incidence of systemic lupus erythematosus in a population-based cohort using revised 1997 American College of Rheumatology and the 2012 Systemic Lupus International Collaborating Clinics classification criteria. Lupus 2016, 26: 240-247. PMID: 27365370, PMCID: PMC5201452, DOI: 10.1177/0961203316657434.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusACR-97SLICC-12Lupus erythematosusSystemic Lupus International Collaborating Clinics classification criteriaSystemic Lupus International Collaborating Clinics (SLICC) groupClassification criteriaIncidence of lupusIncident SLE patientsRenal-limited diseaseSLICC-12 criteriaRochester Epidemiology ProjectACR classification criteriaPopulation-based cohortOlmsted CountyMedian durationSLE patientsAdjusted incidenceAmerican CollegeClinic groupHigh incidenceImmunologic criteriaNeurologic criteriaPatientsIncidence
2015
Autoimmune myelofibrosis with pancytopenia as a presenting manifestation of systemic lupus erythematosus responsive to mycophenolate mofetil
Ungprasert P, Chowdhary V, Davis M, Makol A. Autoimmune myelofibrosis with pancytopenia as a presenting manifestation of systemic lupus erythematosus responsive to mycophenolate mofetil. Lupus 2015, 25: 427-430. PMID: 26537421, DOI: 10.1177/0961203315615221.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusAutoimmune myelofibrosisLupus erythematosusBullous skin lesionsPresenting manifestationPeripheral destructionHematological abnormalitiesSkin lesionsMofetilErythematosusPancytopeniaMyelofibrosisManifestationsLeucopeniaThrombocytopeniaAnemiaGlucocorticoidsLesionsAbnormalitiesEpidemiology of Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus in a Predominantly White Population in the United States
Jarukitsopa S, Hoganson DD, Crowson CS, Sokumbi O, Davis MD, Michet CJ, Matteson EL, Maradit Kremers H, Chowdhary VR. Epidemiology of Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus in a Predominantly White Population in the United States. Arthritis Care & Research 2015, 67: 817-828. PMID: 25369985, PMCID: PMC4418944, DOI: 10.1002/acr.22502.Peer-Reviewed Original ResearchConceptsCutaneous lupus erythematosusSystemic lupus erythematosusSex-adjusted incidenceLupus erythematosusPrevalence of SLEClassic discoid lupus erythematosusBullous lupus erythematosusRochester Epidemiology ProjectSex-adjusted prevalenceDiscoid lupus erythematosusRheumatology classification criteriaWhite populationUS white populationCLE casesOlmsted CountyLupus panniculitisSLE casesMedical recordsErythematosusEpidemiologic studiesAmerican CollegePrevalenceIncidenceOlder adultsAgeSynovial Infiltration in Human T Lymphotropic Virus Type I–Associated Adult T Cell Leukemia/Lymphoma
Koster MJ, McPhail ED, Chowdhary VR. Synovial Infiltration in Human T Lymphotropic Virus Type I–Associated Adult T Cell Leukemia/Lymphoma. Arthritis & Rheumatology 2015, 67: 945-945. PMID: 25604902, DOI: 10.1002/art.39038.Peer-Reviewed Original Research
2013
An unusual cause of diffuse pulmonary infiltrates
Krause ML, Boland JM, Maleszewski JJ, Gilbertson JR, Chowdhary VR. An unusual cause of diffuse pulmonary infiltrates. Arthritis Care & Research 2013, 65: 487-490. PMID: 23002027, DOI: 10.1002/acr.21860.Peer-Reviewed Original Research
2012
Increased Risk of Systemic Lupus Erythematosus in 29,000 Patients with Biopsy-verified Celiac Disease
Ludvigsson JF, Rubio-Tapia A, Chowdhary V, Murray JA, Simard JF. Increased Risk of Systemic Lupus Erythematosus in 29,000 Patients with Biopsy-verified Celiac Disease. The Journal Of Rheumatology 2012, 39: 1964-1970. PMID: 22859356, PMCID: PMC3463642, DOI: 10.3899/jrheum.120493.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusRisk of SLEHazard ratioCeliac diseaseLupus erythematosusAbsolute riskExcess riskGeneral populationPossible associationBiopsy-verified celiac diseaseIncident systemic lupus erythematosusSweden's 28 pathology departmentsSwedish Total Population RegisterDepartment of RheumatologySwedish Patient RegisterYears of followupPopulation-based studyTotal Population RegisterSimilar risk estimatesSLE diagnosisPatient RegisterCase seriesCox regressionCD diagnosisPathology department
2008
Liver Involvement in Systemic Lupus Erythematosus: Case Review of 40 Patients
Chowdhary VR, Crowson CS, Poterucha JJ, Moder KG. Liver Involvement in Systemic Lupus Erythematosus: Case Review of 40 Patients. The Journal Of Rheumatology 2008, 35: 2159-2164. PMID: 18793002, DOI: 10.3899/jrheum.080336.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusEndstage liver diseaseLiver diseasePortal hypertensionLiver involvementViral hepatitisLupus erythematosusLiver disease-free survivalNonalcoholic fatty liver diseaseCoexistent liver diseaseSubclinical liver involvementDevelopment of cirrhosisLiver enzyme abnormalitiesAlanine aminotransferase levelsDisease-free survivalRetrospective chart reviewCohort of patientsFatty liver diseasePrimary biliary cirrhosisAlkaline phosphatase levelsClinical diagnostic groupsAutoimmune hepatitisCryptogenic cirrhosisHepatitis CAminotransferase levels
2000
Sweet's syndrome and Pneumocystis carinii pneumonia: two sequelae of low‐dose cytosine arabinoside therapy in a patient with acute myeloid leukemia
Chowdhary V, Nityanand S, Prasad K, Pandey R, Dabadghao S. Sweet's syndrome and Pneumocystis carinii pneumonia: two sequelae of low‐dose cytosine arabinoside therapy in a patient with acute myeloid leukemia. European Journal Of Haematology 2000, 65: 72-73. PMID: 10914942, DOI: 10.1034/j.1600-0609.2000.9c177.x.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaPneumocystis carinii pneumoniaMyeloid leukemiaCarinii pneumoniaLow‐dose cytosine arabinoside therapyAcute febrile neutrophilic dermatosisAttainment of remissionFebrile neutrophilic dermatosisLow-dose cytosineNeutrophilic dermatosisSweet's syndromeImmunosuppressive potentialNeutrophil functionLow doseLow dosesLeukemiaPneumoniaSyndromeDirect effectRemissionSequelaePatientsDermatosesTherapyDose